Skip to main content

Table 1 Patient Demographics

From: A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

Age (years)

n

10

Mean

69.6

Range

63–79

Race/Ethnicity

n

10

Caucasians

9

African Americans

1

Baseline PSA (ng/mL)

n

10

Mean

434

Range

9–1424

Baseline Anti-Vaccinia Titer

n

10

Mean

700

Range

200–1600